- Home
- ALLE vs NBIX Comparison
ALLE vs NBIX Comparison
Compare ALLE & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALLE | NBIX |
|---|---|---|
| Founded | 2013 | 1992 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9B | 14.4B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | ALLE | NBIX |
|---|---|---|
| Price | $159.24 | $155.51 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 19 |
| Target Price | $172.22 | ★ $173.79 |
| AVG Volume (30 Days) | 787.1K | ★ 969.9K |
| Earning Date | 10-23-2025 | 10-28-2025 |
| Dividend Yield | ★ 1.28% | N/A |
| EPS Growth | ★ 13.70 | 12.44 |
| EPS | ★ 7.39 | 4.19 |
| Revenue | ★ $3,979,700,000.00 | $2,682,700,000.00 |
| Revenue This Year | $10.07 | $23.76 |
| Revenue Next Year | $6.53 | $18.01 |
| P/E Ratio | ★ $21.53 | $37.10 |
| Revenue Growth | 6.87 | ★ 19.61 |
| 52 Week Low | $116.57 | $84.23 |
| 52 Week High | $180.68 | $157.67 |
Technical Indicators
Market Signals| Indicator | ALLE | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 35.06 | 64.81 |
| Support Level | $163.27 | $150.26 |
| Resistance Level | $167.01 | $154.35 |
| Average True Range (ATR) | 3.10 | 4.16 |
| MACD | 0.01 | 1.07 |
| Stochastic Oscillator | 2.11 | 93.25 |
Price Performance
Historical ComparisonAbout ALLE Allegion plc
Allegion is a global security products company with a portfolio of leading brands such as Schlage, Von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2024, Allegion generated over 75% of sales in the United States. The company primarily competes with Sweden-based Assa Abloy, Switzerland-based Dormakaba, and US-based Fortune Brands Innovations.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.